-transparent.png){kind=logo}
A trial to compare the therapeutic potential of 1200 mg. azapropazone daily with 3.9 g. aspirin daily was carried out in 108 out-patients with rheumatoid arthritis over a 14-day period. Analysis of results from the 85 patients with completed assessment data (49 on azapropazone; 36 on aspirin) showed that azapropazone was better than aspirin from the point of view of pain relief, number of days patients were withdrawn prematurely from the trial, and patient satisfaction with treatment. The differences, however, were not statistically significant. The authors compare the results obtained in this trial with those obtained previously from trials with 13 other antirheumatic drugs using the same method.
P M Brooks, and
D I Mason, and
R McNeil, and
J A Anderson, and
W W Buchanan
January 1976,
Current medical research and opinion,
P M Brooks, and
D I Mason, and
R McNeil, and
J A Anderson, and
W W Buchanan
January 1976,
Current medical research and opinion,
P M Brooks, and
D I Mason, and
R McNeil, and
J A Anderson, and
W W Buchanan
January 1974,
Current medical research and opinion,
P M Brooks, and
D I Mason, and
R McNeil, and
J A Anderson, and
W W Buchanan
November 1976,
The Practitioner,
P M Brooks, and
D I Mason, and
R McNeil, and
J A Anderson, and
W W Buchanan
January 1981,
Current medical research and opinion,
P M Brooks, and
D I Mason, and
R McNeil, and
J A Anderson, and
W W Buchanan
April 1956,
Canadian Medical Association journal,
P M Brooks, and
D I Mason, and
R McNeil, and
J A Anderson, and
W W Buchanan
October 1968,
Arthritis and rheumatism,
P M Brooks, and
D I Mason, and
R McNeil, and
J A Anderson, and
W W Buchanan
November 2016,
International immunopharmacology,
P M Brooks, and
D I Mason, and
R McNeil, and
J A Anderson, and
W W Buchanan
November 2015,
Human immunology,
P M Brooks, and
D I Mason, and
R McNeil, and
J A Anderson, and
W W Buchanan
January 1976,
Current medical research and opinion,
